Home / Therapeutic Area / Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014

Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014

Published: May 2015 | No Of Pages: 386 | Published By: La Merie Publishing
Biosimilar and Biosuperior Therapeutic Antibodies 2014
The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodies 2014 provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of March 2014.
Marketed antibodies are attractive for companies to create next generation variants and  biosimilar copies because they represent clinically and commercially validated products. New technologies such as Fc engineering, polyclonal mixtures, antibody drug conjugates or bispecific molecules as well as the expiration of patents stimulate the discovery and development of biosimilar and biosuperior/biobetter molecules.
Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 75.7 bln in the year 2013. Cumulated 2013 sales of branded therapeutic antibodies approaching patent expiry and, therefore, target of biosimilar substitution, reached US$ 58.6 bln.
The report lists specifically for each target the branded products with their 2013 sales and up-side indications in development, as well as follower, biosuperior and biosimilar antibody drug candidates in development.
2013 Sales data are provided for
  • Rituxan/MabThera
  • Arzerra
  • Zevalin
  • Gazyva
  • Herceptin
  • Perjeta
  • Kadcyla
  • Avastin
  • Zaltrap
  • Erbitux
  • Vectibix
  • Yervoy
  • Adcetris
  • Poteligeo
  • Humira
  • Enbrel
  • Remicade
  • Simponi
  • Cimzia
  • Orencia
  • Nulojix
  • Ilaris
  • Arcalyst
  • Tysabri
  • Soliris
  • Xolair
  • Stelara
  • Actemra/RoActemra
  • Benlysta
  • Lemtrada
  • ReoPro
  • Nplate
  • Prolia
  • Lucentis
  • Eylea
  • Synagis
The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior antibodies against commercially and clinically validated targets:
  • CD20
  • Her2
  • VEGF
  • TNF
  • EGF-R
  • CD52
  • GPIIb/IIIa
  • B7.1/B7.2 (CD80/CD86)
  • IL-6R
  • Alpha4/beta1/7 integrin
  • IgE
  • RSV
  • Complement C5
  • IL-12/IL-23
Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
1. 2013 Sales of Recombinant Therapeutic Antibodies
Overview and Summary of Antibody Sales 2013
Cancer Antibody Sales 2013
Inflammatory and Autoimmune Antibody Sales 2013
Cardiohematometabolic Antibody Sales 2013
Ophthalmic Antibody Sales 2013
Antiviral Antiody Sales 2013
2. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors
Marketed CD20 Antibodies & Sales
Rituxan/MabThera Pipeline & Sales
Arzerra Pipeline & Sales
Gazyva Pipeline & Sales
Bexxar & Zevalin Pipeline & Sales
Biosuperior CD20 Antibodies
Biosimilar CD20 Antibodies
Rituxan/MabThera (rituximab) Biosimilars
Arzerra (ofatumumab) Biosimilars
3. Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors
Marketed Her2 Antibodies
Herceptin Sales & Pipeline
Perjeta Sales & Pipeline
Kadcyla Sales & Pipeline
Trastuzumab Biobetters/Biosuperiors
Engineered Her2 Antibodies
Bi- and Multispecific Her2 Antibodies
Her2 Antibody-Drug Conjugates
Her2 Imaging Antibodies
Trastuzumab Biosimilars
4. VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors
4a. Bevacizumab Biosimilars and Biosuperiors
Marketed VEGF Antibodies
Avastin Sales & Pipeline
Zaltrap Sales & Pipeline
“Next Generation Avastin” Pipeline
Anti-VEGF Antibody Pipeline
Anti-VEGF-Receptor Antibody Pipeline
Bispecific Anti-VEGF Antibody Pipeline
Avastin Biosimilar Pipeline
4b. Ranibizumab Biosimilars and Biosuperiors
Marketed VEGF Antibody
Lucentis Sales & Pipeline
Eylea Sales & Pipeline
“Next Generation Lucentis” Pipeline
Lucentis Biosimilar Pipeline
5. EGF-R Antibodies –Biosimilars and Biosuperiors
Marketed EGF-R Antibodies
Erbitux Sales & Pipeline
Vectibix Sales & Pipeline
Nimotuzumab Pipeline
EGF-R Antibody Biobetters/Biosuperiors
Engineered EGF-R Antibodies
Bi- and Multispecific EGF-R Antibodies
EGF-R Antibody-Drug Conjugates
EGF-R Antibody Biosimilars
Cetuximab Biosimilars
Panitumumab Biosimilars
6. TNF Antibodies –Biosimilars and Biosuperiors
Marketed TNF Antibodies
Humira Sales & Pipeline
Remicade Sales & Pipeline
Enbrel Sales & Pipeline
Simponi Sales & Pipeline
Cimzia Sales & Pipeline
Biosuperior / Biobetter TNF Antibodies
Biosimilar TNF Antibodies
Humira Biosimilar Antibody Pipeline
Remicade Biosimilar Antibody Pipeline
Enbrel Biosimilar Antibody Pipeline
Simponi Biosimilar Antibody Pipeline
Cimzia Biosimilar Antibody Pipeline
7. IgE Antibodies: Xolair, Biosuperiors & Biosimilars
Marketed IgE Antibody Sales & Pipeline
Biosuperior IgE Antibodies
Biosimilar IgE Antibodies
8. Interleukin-6 Receptor (IL-6R) Antibodies: Actemra, Biosuperiors & Biosimilars
Marketed Il-6R Antibody Sales & Pipeline
Biosuperior IL-6(R) Antibodies
Biosimilar IL-6(R) Antibodies
9. GPIIb/IIIa Antibodies: ReoPro, Biosuperios & Biosimilars
Marketed GPIIb/IIIa Antibody Sales & Pipeline
Biosimilar GPIIb/IIIa Antibodies
10. CD52 Antibodies: Lemtrada, Biosuperios & Biosimilars
Marketed CD52 Antibody Sales & Pipeline
Biosimilar CD52 Antibodies
11. Apha4/beta1/7 Antibodies: Tysabri, Biosuperiors & Biosimilars
Marketed Alpha4/beta1/7 Antibody Sales & Pipeline
Biosimilar Alpha4/beta1/7 Antibodies
12. Complement C5 Antibodies: Soliris, Biosuperiors & Biosimilars
Marketed C5 Antibody Sales & Pipeline
Biosuperior C5 Antibodies
Biosimilar C5 Antibodies
13. Respiratory Syncytial Virus (RSV): Synagis, Biosuperiors & Biosimilars
RSV Antibody Sales & Pipeline
Biosuperior RSV Antibodies
Biosimilar RSV Antibodies
14. RANKL Antibodies: Prolia/XGEVA, Biosuperiors & Biosimilars
Marketed RANKL Antibody Sales & Pipeline
Biosuperior RANKL Antibodies
15. CD80/86 (B7-1/B7-2) Antibodies: Orencia; Nulojix, Biosuperiors & Biosimilars
CD80/86 Antibody Sales & Pipeline
Biosuperior CD80/86 Antibodies
Biosimilar CD80/86 Antibodies
16. Interleukin-12/-23 Antibodies: Stelara, Biosuperiors & Biosimilars
Marketed IL-12/-23 Antibody Sales & Pipeline
Biosimilar IL-12/-23 Antibodies
17.  Corporate  Biosimilar and Biosuperior Therapeutic Antibody Pipelines
Choose License Type
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +